Publications
Shi Y, Dincheva-Vogel L, Ayemoba CE, Fung JP, Bergamaschi C, Pavlakis GN, Farzaneh F, Gaensler KML. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice. Blood advances. 2018. PMID: 30482760
Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. Head & neck. 2018. PMID: 30478962
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nature medicine. 2018. PMID: 30478424
Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B, Dana-Farber Cancer Institute Inflammatory Breast Cancer Program. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clinical breast cancer. 2018. PMID: 30584057
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nature medicine. 2018. PMID: 30478424
Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. American journal of hematology. 2018. PMID: 30394566
Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. American journal of hematology. 2018. PMID: 30394566
Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018. PMID: 30464040
Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018. PMID: 30464040
Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical lung cancer. 2018. PMID: 30553716
Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical lung cancer. 2018. PMID: 30553716
Borno HT, Lichtensztajn DY, Gomez SL, Palmer NR, Ryan CJ. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. Cancer. 2018. PMID: 30444526
Fung M, Zompi S, Seng H, Hollemon D, Parham A, Hong DK, Bercovici S, Dolan E, Lien K, Teraoka J, Logan AC, Chin-Hong P. Plasma Cell-Free DNA Next-Generation Sequencing to Diagnose and Monitor Infections in Allogeneic Hematopoietic Stem Cell Transplant Patients. Open forum infectious diseases. 2018. PMID: 30581881
Fung M, Zompi S, Seng H, Hollemon D, Parham A, Hong DK, Bercovici S, Dolan E, Lien K, Teraoka J, Logan AC, Chin-Hong P. Plasma Cell-Free DNA Next-Generation Sequencing to Diagnose and Monitor Infections in Allogeneic Hematopoietic Stem Cell Transplant Patients. Open forum infectious diseases. 2018. PMID: 30581881
Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, Li PJ, Diolaiti ME, Ashworth A, Marson A. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Cell. 2018. PMID: 30449619
Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, Li PJ, Diolaiti ME, Ashworth A, Marson A. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Cell. 2018. PMID: 30449619
Lancman G, Arinsburg S, Jhang J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richter J, Chari A. Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. Frontiers in immunology. 2018. PMID: 30498492
Borno HT, Small EJ. Apalutamide and its use in the treatment of prostate cancer. Future oncology (London, England). 2018. PMID: 30426794
Borno HT, Small EJ. Apalutamide and its use in the treatment of prostate cancer. Future oncology (London, England). 2018. PMID: 30426794
Park JC, Gourin CG, Kiess AP, Mehra R, Forastiere AA, Kang H. Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. Head & neck. 2018. PMID: 30421818